PPARA and atherosclerosis: As discussed above, LOCAT found no association of the PPARA Leu162Valpolymorphism with variations in serum lipids [50].However, this study did observe that carriers of the PPARA Val162allele showed significantly less progression of atherosclerosis in both gemfibrozil-treatedand untreated groups [50].No pharmacogenetic (i.e., treatment by genotype) interaction was found [50].